•	Malaysia seeks a compulsory license for Abbott's anti AIDS "Kaletra"

•	Brazil's Counterfeit Medicine Problem Triples in 4 Years
•	Two Israeli Men Sentenced for Smuggling Counterfeit and Misbranded Cialis into the United States

•	Manufacturing round-up: new facilities in India

•	Kenya court ruling, a boost for Indian generics exports
•	Mylan Announces Settlement Agreement for its First-to-File Generic Version of Unveil
•	Mylan Launches First Generic Version of Doryx 150 mg
•	Mylan Launches Generic Lipitor in Five European Countries

•	China Continues Efforts to Gain Global Pharmaceutical Market Share
•	China wants vaccine production innovation to boost local sector
•	China's Bengaluru-based Cdymax plans public issue, to list in NSE, Shanghai soon
•	Cipla cuts price of generic Nexavar in India by 75 percent
•	Exporters demand some capital investment in overseas market
•	Merck KGaA cuts manufacturing workers in major staff reduction; Novartis plant goes modular
•	US set to re-emerge as biggest market for Indian merchandise

•	Sub-Saharan is "attractive" emerging market, says Sandoz

•	Novartis to acquire Fougera Pharmaceuticals for $1.5 billion
•	Piramal Healthcare Limited to Buy US Drug Data Firm for $635 Million
•	Watson Agrees To Acquire ActavisFor Potential $5.94B
•	Watson to Become Third Largest Global Generics Company Following Actavis Takeover
•	Watson to Buy Actavis for $5.6 Billion in Generics Deal

•	Industry responses to cargo thefts face greater FDA scrutiny

•	7 Emerging Anti-Aging Supplements

•	Gene Patent Case Heads Back to Court
•	Johnson & Johnson declines Invitation to join Medicines Patent Pool
•	Merck wins patent infringement lawsuits against Mylan Pharma
•	New Erectile Dysfunction Drug Okayed by FDA
•	Patients before patents in healthcare
•	Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx
•	US Appeals Court Upholds Abilify Patent

•	CDSCO upgrades Gujarat's sub zonal office to zonal level
•	Pharma news  DoP moots National Centre for R&D in bulk drugs for helping sector

•	The Biggest R&D Spenders in Biopharma
•	US Government Is 'Largest Funder of Global Health R&D'

•	Indian companies to participate in CPhl SEA exhibition
•	Pharmexcil proposes collaboration with India-Japan Pharma Alliance in Japan

•	26 Drugs Facing FDA Approval in 2012
•	Claris Lifesciences yet to get USFDA clearance
•	FDA clampdown driving Indian compliance investment; ICRA
•	FDA issues import alerts against 22 Chinese heparin suppliers
•	Merck Wins U.S. ZETIA (ezetimibe)/ VYTORIN (ezetimibe/simvastatin) Patent Infringement Lawsuit
•	New EMA guidelines for Release Testing of Drugs
•	U.K. urged to ban drug exports; Hospira recalls pain med

•	#Johnson & #Johnson fined $1.1bn in Risperdal case
•	Abbott to pay $1.6 billion to settle US Depakote investigation
•	Bolus of FDA Warning Letters to Foreign Manufacturers Spans Regions and Product Types
•	Half of FY11 FDA GMP warning letters tied to batch failures
•	Pills Containing Heavy Metal Toxins Found In Circulation In China

•	EC offers €2m prize for system to improve vaccine stability
•	Polyphone-enriched soyabean flour shows blood sugar benefits
•	Remote-Controlled Gene Expression
•	Study Focuses on Curcumin to Treat Cancer
•	Study Identifies Possible Protective Blood Factors Against Type 2 Diabetes